Cempra Inc (CEMP) : Aisling Capital reduced its stake in Cempra Inc by 45.6% during the most recent quarter end. The investment management company now holds a total of 1,193,060 shares of Cempra Inc which is valued at $17.6 Million after selling 1,000,000 shares in Cempra Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Cempra Inc makes up approximately 3.99% of Aisling Capital’s portfolio.
Other Hedge Funds, Including , D.a. Davidson added CEMP to its portfolio by purchasing 1,600 company shares during the most recent quarter which is valued at $23,600.Hap Trading boosted its stake in CEMP in the latest quarter, The investment management firm added 39 additional shares and now holds a total of 42,500 shares of Cempra Inc which is valued at $626,875. Cempra Inc makes up approx 0.07% of Hap Trading’s portfolio.Blackrock Fund Advisors boosted its stake in CEMP in the latest quarter, The investment management firm added 180,832 additional shares and now holds a total of 1,471,812 shares of Cempra Inc which is valued at $21.7 Million. Cempra Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Teachers Advisors Inc boosted its stake in CEMP in the latest quarter, The investment management firm added 11,108 additional shares and now holds a total of 80,708 shares of Cempra Inc which is valued at $1.3 Million. Lebenthal Lisanti Capital Growth sold out all of its stake in CEMP during the most recent quarter. The investment firm sold 20,045 shares of CEMP which is valued $314,105.
Cempra Inc opened for trading at $17.15 and hit $17.76 on the upside on Wednesday, eventually ending the session at $17.49, with a gain of 3.43% or 0.58 points. The heightened volatility saw the trading volume jump to 7,82,810 shares. Company has a market cap of $843 M.
On the company’s financial health, Cempra Inc reported $-0.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 2, 2016. Analyst had a consensus of $-0.64. The company had revenue of $2.70 million for the quarter, compared to analysts expectations of $3.94 million. The company’s revenue was down -80.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.41 EPS.
Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product solithromycin is being developed in oral capsules intravenous or IV and suspension formulations initially for the treatment of community acquired bacterial pneumonia or CABP an infection of the respiratory tract. The Company’s second product is Taksta an antibiotic known as fusidic acid that has been used for decades outside the United States including Western Europe but which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.